Category : Seeking Alpha

FOR KING + COUNTRY TEASE A FIERY NEW SEASON WITH UPCOMING SINGLE "WORLD ON FIRE" -- ARRIVING OCTOBER 3

NASHVILLE, Tenn., Sept. 17, 2025 /PRNewswire/ -- The wait is almost over. Four-time GRAMMY® Award-winning Curb Records duo for KING + COUNTRY announce the arrival of their brand-new single, "World on Fire feat. Taylor Hill," releasing everywhere on O...

Qodo Named a Visionary in the 2025 Gartner® Magic Quadrant™ for AI Code Assistants

Recognized for Completeness of Vision and Ability to Execute NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Qodo, the Agentic Code Quality platform, today announced that Qodo has been positioned by Gartner as a Visionary in the Magic Quadrant for AI Code A...

Microbix Client Labquality Introduces Novel EQA Scheme at ESCV

Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck Cancers Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck Cancers

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

Castle Biosciences has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek.

Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: 1)

Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis

Denifanstat met all primary and secondary endpoints versus placebo

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR study evaluating brepocitinib in der...

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at...

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea Six poster presentations showcase clinical and real-world data in major depressive dis...

Anfield Receives Approval to List on NASDAQ

VANCOUVER, British Columbia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Anfield Energy Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or the “Company”) is pleased to announce it has received approval to list its common shares (the “Shares”) on...

Carlton Precious Announces Filing of Notice of Intention to Sell Athena Gold Corporation Common Shares

TORONTO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Carlton Precious Inc. (TSX-V: CPI | OTCQB: CPIFF) ("Carlton Precious" or the "Company") announces that the Company has filed a notice of intention to distribute securities (Form 45-102F1) (the “Notice”) i...

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 and was well tolerated in PROGRESS Phase 2b study Pilavapadin 10 mg resulted in a two-point reduction from baseline in average daily pain...

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

The study, published in The European Journal of Ophthalmology, included 29 publications and concluded that favorable long-term safety and efficacy profiles make OMNI a beneficial treatment option for patients with primary open-angle glaucoma The stud...